DEVELOPING ONE-TIME GENE THERAPIES FOR EYE DISEASES
Gyroscope Therapeutics is a clinical-stage gene therapy company developing gene therapy beyond rare disease to treat diseases of the eye that cause vision loss and blindness. The company was acquired by Novartis, a leading global medicines company, in February 2022.
Gyroscope’s lead investigational gene therapy, GT005, is currently being evaluated in Phase II clinical trials for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of blindness. GT005 has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of people with GA.
Guided by a mission to preserve sight and fight the devastating impact of blindness, Gyroscope has built a global organisation combining discovery, research, drug development, a manufacturing platform and surgical delivery capabilities.
We know that our people, with their passion for patients, will drive to deliver on our promise – vision for life.
People living with AMD are our guide. We seek to anticipate their needs and understand their journey. This drives us to develop innovative treatments to fight the devastating impact of AMD.
Here are the stories of some of the people that inspire us every day.
OUR CLINICAL TRIALS
Our clinical development programme is built on the discoveries of our founders and research scientists related to the role of immune response in dry age-related macular degeneration (AMD).
Find out more on our clinical trials.